Current treatment standards and future strategies in mantle cell lymphoma

M. Dreyling(Ludwig-Maximilians-Universität München), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Oliver Weigert(German Cancer Research Center)

Annals of Oncology

June 1, 2008

10.1093/annonc/mdn193

Cited by 23

Related Papers

A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling

|New England Journal of Medicine|2006|1k

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

|Blood|2007|971

A 17-gene stemness score for rapid determination of risk in acute leukaemia

|Nature|2016|916

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2017|736

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

|The Lancet Oncology|2015|613